Sero-surveillance for SARS-CoV-2 infection among healthcare providers in four hospitals in Thailand one year after the first community outbreak

Kittikraisak, Wanitchaya; Piyaraj, Phunlerd; Vachiraphan, Apichat; Wongrapee, Thanapat; Punjasamanvong, Somsak; Hunsawong, Taweewun; Sinthuwattanawibool, Chalinthorn; Leepiyasakulchai, Chaniya; Yoocharoen, Pornsak; Azziz‐Baumgartner, Eduardo; Mott, Joshua A.; Chottanapund, Suthat

doi:10.1371/journal.pone.0254563

Cited by 8 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, only one participant could be confirmed by Euroimmune® ELISA, resulting in a seroprevalence of 0.015% [ 20 ]. Furthermore, the serosurveillance of 600 health care providers from 4 hospitals for one year after the first case was detected in Thailand yielded only one seropositive participant (seroprevalence 0.2%) [ 21 ]. Notably, this individual was positive for IgG antibodies against the S protein but not IgG antibodies against the N protein, as determined by Euroimmune® ELISA.…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves

et al. 2022

View full text Add to dashboard Cite

This study determined the presence of anti-SARS-CoV-2 antibodies in 4964 individuals, comprising 300 coronavirus disease-19 (COVID-19) prepandemic serum samples, 142 COVID-19 patients, 2113 individuals at risk due to their occupations, 1856 individuals at risk due to sharing workplaces or communities with COVID-19 patients, and 553 Thai citizens returning after spending extended periods of time in countries with a high disease prevalence. We recruited participants between May 2020 and May 2021, which spanned the first two epidemic waves and part of the third wave of the COVID-19 outbreaks in Thailand. Their sera were tested in a microneutralization and a chemiluminescence immunoassay for IgG against the N protein. Furthermore, we performed an immunofluorescence assay to resolve discordant results between the two assays. None of the prepandemic sera contained anti-SARS-CoV-2 antibodies, while antibodies developed in 88% (15 of 17) of the COVID-19 patients at 8–14 days and in 94–100% of the patients between 15 and 60 days after disease onset. Neutralizing antibodies persisted for at least 8 months, longer than IgG antibodies. Of the 2113 individuals at risk due to their occupation, none of the health providers, airport officers, or public transport drivers were seropositive, while antibodies were present in 0.44% of entertainment workers. Among the 1856 individuals at risk due to sharing workplaces or communities with COVID-19 patients, seropositivity was present in 1.9, 1.5, and 7.5% of the Bangkok residents during the three epidemic waves, respectively, and in 1.3% of the Chiang Mai people during the first epidemic wave. The antibody prevalence varied between 6.5 and 47.0% in 553 Thai people returning from high-risk countries. This serosurveillance study found a low infection rate of SARS-CoV-2 in Thailand before the emergence of the Delta variant in late May 2021. The findings support the Ministry of Public Health’s data, which are based on numbers of patients and contact tracing.

show abstract

Section: Discussionmentioning

confidence: 99%

Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Several of these cohorts are also examining COVID-19 vaccine effectiveness to SARS-CoV-2 variants by dosing schedules. In Thailand, the Ministry of Health and Influenza Division field staff leveraged close partnerships with academic institutions and hospitals to conduct a serosurvey among health care personnel 1 year after the start of the pandemic ( 32 ) and after COVID-19 vaccination ( 33 ). The 13-country PAHO Network for the Evaluation of Vaccine Effectiveness in Latin America and the Caribbean, known as REVELAC-I for its acronym in Spanish ( 34 ), was activated to assess COVID-19 vaccine effectiveness among hospitalized persons in countries such as Paraguay ( 35 ); CDC supported this work with financial and technical resources.…”

Section: Expansion Of Existing Influenza Evaluation Projects To Inclu...mentioning

confidence: 99%

Leveraging International Influenza Surveillance Systems and Programs during the COVID-19 Pandemic

Marcenac¹,

McCarron²,

Davis³

et al. 2022

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

A network of global respiratory disease surveillance systems and partnerships has been built over decades as a direct response to the persistent threat of seasonal, zoonotic, and pandemic influenza. These efforts have been spearheaded by the World Health Organization, country ministries of health, the US Centers for Disease Control and Prevention, nongovernmental organizations, academic groups, and others. During the COVID-19 pandemic, the US Centers for Disease Control and Prevention worked closely with ministries of health in partner countries and the World Health Organization to leverage influenza surveillance systems and programs to respond to SARS-CoV-2 transmission. Countries used existing surveillance systems for severe acute respiratory infection and influenza-like illness, respiratory virus laboratory resources, pandemic influenza preparedness plans, and ongoing population-based influenza studies to track, study, and respond to SARS-CoV-2 infections. The incorporation of COVID-19 surveillance into existing influenza sentinel surveillance systems can support continued global surveillance for respiratory viruses with pandemic potential.

show abstract

“…A study among non-healthcare workers with a high potential of exposure to SARS-CoV-2 in the northern regions (the Chiang Mai and Lamphun provinces) during the second wave of the outbreak (November 2020-January 2021) reported 0.9% (n = 1651) positive results for antibody tests [10]. Another study in healthcare workers in the Bangkok metropolitan area, and the western and eastern regions of Thailand from January to March 2021 reported that the positive rate for SARS-Cov-2 IgG-spike antibodies was 0.2% (n = 600) [11]. However, no data from serological survey studies conducted after the outbreak of the fourth wave in Thailand are available, while several countries reported various prevalence rates of COVID-19 seropositivity after the delta outbreak.…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021

et al. 2022

View full text Add to dashboard Cite

Between the first case of COVID-19 in January 2020 and the end of 2021, Thailand experienced four waves of the epidemic. The third and fourth waves were caused by the alpha and delta strains from April 2021 to November 2021. Serosurveillance studies provide snapshots of the true scale of the outbreak, including the asymptomatic infections that could not be fully captured by a hospital-based case detection system. We aimed to investigate the distribution of SARs-CoV-2 seroprevalence in unvaccinated adults after the delta wave outbreak. From November to December 2021, we conducted a cross-sectional survey study in 12 public health areas (PHAs) across Thailand. A total of 26,717 blood samples were collected and tested for SARs-CoV-2 antibodies (anti-S IgG) using a qualitative immunoassay. The results showed that seropositive prevalence in this cohort was 1.4% (95% CI: 1.24 to 1.52). The lowest prevalence was in the northern region (PHA 1) and in central Thailand (PHA 3) at 0.4% (95% CI: 0.15 to 0.95), while the highest was in the southern region of Thailand (PHA 12) at 5.8% (95% CI: 4.48 to 7.29). This seropositive prevalence was strikingly lower than the reports from other countries. Our serosurveillance results suggest that the vaccination of unvaccinated groups should be accelerated, especially in the public health areas with the lowest seroprevalence.

show abstract

Sero-surveillance for SARS-CoV-2 infection among healthcare providers in four hospitals in Thailand one year after the first community outbreak

Cited by 8 publications

References 17 publications

Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves

Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves

Leveraging International Influenza Surveillance Systems and Programs during the COVID-19 Pandemic

SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021

Contact Info

Product

Resources

About